Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Virol ; 96(4): e29555, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38546037

ABSTRACT

In this study, we demonstrated the antiviral efficacy of hesperetin against multiple poxviruses, including buffalopox virus (BPXV), vaccinia virus (VACV), and lumpy skin disease virus (LSDV). The time-of-addition and virus step-specific assays indicated that hesperetin reduces the levels of viral DNA, mRNA, and proteins in the target cells. Further, by immunoprecipitation (IP) of the viral RNA from BPXV-infected Vero cells and a cell-free RNA-IP assay, we demonstrated that hesperetin-induced reduction in BPXV protein synthesis is also consistent with diminished interaction between eukaryotic translation initiation factor eIF4E and the 5' cap of viral mRNA. Molecular docking and MD simulation studies were also consistent with the binding of hesperetin to the cap-binding pocket of eIF4E, adopting a conformation similar to m7GTP binding. Furthermore, in a BPXV egg infection model, hesperetin was shown to suppress the development of pock lesions on the chorioallantoic membrane and associated mortality in the chicken embryos. Most importantly, long-term culture of BPXV in the presence of hesperetin did not induce the generation of drug-resistant viral mutants. In conclusion, we, for the first time, demonstrated the antiviral activity of hesperetin against multiple poxviruses, besides providing some insights into its potential mechanisms of action.


Subject(s)
Eukaryotic Initiation Factor-4E , Hesperidin , Vaccinia virus , Animals , Cattle , Chlorocebus aethiops , Chick Embryo , Vero Cells , Molecular Docking Simulation , Vaccinia virus/genetics , Antiviral Agents/pharmacology , RNA, Messenger , Virus Replication
2.
Virulence ; 15(1): 2324711, 2024 12.
Article in English | MEDLINE | ID: mdl-38527940

ABSTRACT

Micro RNAs (miRNAs) have been implicated in the regulation of maturation, proliferation, differentiation, and activation of immune cells. In this study, we demonstrated that miR-29a antagonizes IFN-γ production at early times post-LSDV infection in cattle. miR-29a was predicted to target upstream IFN-γ regulators, and its inhibition resulted in enhanced IFN-γ production in sensitized peripheral blood mononuclear cells (PBMCs). Further, stimulation of PBMCs with LSDV antigen exhibited lower levels of miR-29a, concomitant with a potent cell-mediated immune response (CMI), characterized by an increase in LSDV-specific CD8+ T cell counts and enhanced levels of IFN-γ, which eventually facilitated virus clearance. In addition, a few immunocompromised cattle (developed secondary LSDV infection at ~ 6 months) that failed to mount a potent cell-mediated immune response, were shown to maintain higher miR-29a levels. Furthermore, as compared to the sensitized crossbred cattle, PBMCs from sensitized Rathi (a native Indian breed) animals exhibited lower levels of miR-29a along with an increase in CD8+ T cell counts and enhanced levels of IFN-γ. Finally, we analysed that a ≥ 60% decrease in miR-29a expression levels in the PBMCs of sensitized cattle correlated with a potent CMI response. In conclusion, miR-29a expression is involved in antagonizing the IFN-γ response in LSDV-infected cattle and may serve as a novel biomarker for the acute phase of LSDV infection, as well as predicting the functionality of T cells in sensitized cattle. In addition, Rathi cattle mount a more potent CMI response against LSDV than crossbred cattle.


Subject(s)
Cattle Diseases , Lumpy skin disease virus , MicroRNAs , Animals , Cattle , Cattle Diseases/diagnosis , Cattle Diseases/genetics , CD8-Positive T-Lymphocytes , Leukocytes, Mononuclear , Lumpy skin disease virus/genetics , MicroRNAs/genetics , Polymerase Chain Reaction , Biomarkers
3.
Acta Trop ; 242: 106922, 2023 Jun.
Article in English | MEDLINE | ID: mdl-37031926

ABSTRACT

Countries in the Indian subcontinent are currently facing a deadly epidemic of lumpy skin disease (LSD).  LSD is primarily a disease of cattle. Buffaloes may sometimes develop mild illness, however, other domestic animals are considered resistant to LSD. We confirmed the LSDV infection in camels as evidenced by skin nodules on the body surface of the affected camels, isolation of LSD virus (LSDV) and amplification of LSDV-specific gene segments from the skin nodules (PCR), nucleotide sequencing of the viral genome and, demonstration of anti-LSDV antibodies in serum. Phylogenetic analysis based on nucleotide sequencing of ORF011, ORF012 and ORF036 revealed that the virus (LSDV/Camel/India/2022/Bikaner) is related to the historical NI-2490/Kenya/KSGP-like field strains which are predominantly circulating in the Indian subcontinent. This is the first report wherein LSDV has been to infect camels.


Subject(s)
Lumpy Skin Disease , Lumpy skin disease virus , Animals , Cattle , Lumpy skin disease virus/genetics , Lumpy Skin Disease/epidemiology , Camelus , Phylogeny , Buffaloes , Nucleotides , Disease Outbreaks/veterinary
4.
Virulence ; 14(1): 2190647, 2023 12.
Article in English | MEDLINE | ID: mdl-36919498

ABSTRACT

Lumpy skin disease (LSD) was reported for the first time in India in 2019 and since then, it has become endemic. Since a homologous (LSD-virus based) vaccine was not available in the country, goatpox virus (GPV)-based heterologous vaccine was authorized for mass immunization to induce protection against LSD in cattle. This study describes the evaluation of safety, immunogenicity and efficacy of a new live-attenuated LSD vaccine developed by using an Indian field strain, isolated in 2019 from cattle. The virus was attenuated by continuous passage (P = 50) in Vero cells. The vaccine (50th LSDV passage in Vero cells, named as Lumpi-ProVacInd) did not induce any local or systemic reaction upon its experimental inoculation in calves (n = 10). At day 30 post-vaccination (pv), the vaccinated animals were shown to develop antibody- and cell-mediated immune responses and exhibited complete protection upon virulent LSDV challenge. A minimum Neethling response (0.018% animals; 5 out of 26,940 animals) of the vaccine was observed in the field trials conducted in 26,940 animals. There was no significant reduction in the milk yield in lactating animals (n = 10108), besides there was no abortion or any other reproductive disorder in the pregnant animals (n = 2889). Sero-conversion was observed in 85.18% animals in the field by day 30 pv.


Subject(s)
Lumpy Skin Disease , Lumpy skin disease virus , Viral Vaccines , Animals , Cattle , Female , Chlorocebus aethiops , Lumpy Skin Disease/prevention & control , Lumpy Skin Disease/epidemiology , Lumpy skin disease virus/genetics , Vaccines, Attenuated/adverse effects , Vero Cells , Viral Vaccines/administration & dosage
5.
Antiviral Res ; 189: 105056, 2021 05.
Article in English | MEDLINE | ID: mdl-33711336

ABSTRACT

Emetine is a FDA-approved drug for the treatment of amebiasis. Previously we demonstrated the antiviral efficacy of emetine against some RNA and DNA viruses. In this study, we evaluated the in vitro antiviral efficacy of emetine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and found it to be a low nanomolar (nM) inhibitor. Interestingly, emetine exhibited protective efficacy against lethal challenge with infectious bronchitis virus (IBV; a chicken coronavirus) in the embryonated chicken egg infection model. Emetine treatment led to a decrease in viral RNA and protein synthesis without affecting other steps of viral life cycle such as attachment, entry and budding. In a chromatin immunoprecipitation (CHIP) assay, emetine was shown to disrupt the binding of SARS-CoV-2 mRNA with eIF4E (eukaryotic translation initiation factor 4E, a cellular cap-binding protein required for initiation of protein translation). Further, molecular docking and molecular dynamics simulation studies suggested that emetine may bind to the cap-binding pocket of eIF4E, in a similar conformation as m7-GTP binds. Additionally, SARS-CoV-2 was shown to exploit ERK/MNK1/eIF4E signalling pathway for its effective replication in the target cells. Collectively our results suggest that further detailed evaluation of emetine as a potential treatment for COVID-19 may be warranted.


Subject(s)
Antiviral Agents , Emetine , Infectious bronchitis virus/drug effects , RNA, Viral/metabolism , SARS-CoV-2/drug effects , Animals , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , Chick Embryo , Chlorocebus aethiops , Coronavirus Infections/drug therapy , Emetine/pharmacology , Emetine/therapeutic use , Eukaryotic Initiation Factor-4E/metabolism , Protein Binding/drug effects , RNA, Messenger/metabolism , Signal Transduction , Vero Cells
6.
J Equine Vet Sci ; 94: 103237, 2020 11.
Article in English | MEDLINE | ID: mdl-33077064

ABSTRACT

The present study was conducted with the hypothesis that addition of cholesterol to the extender would stabilize the sperm membranes by increasing the cholesterol-to-phospholipid (C:P) ratio and would result in an improved post-thaw semen quality and reduce oxidative stress in the jack (Martina franca) semen. Forty-eight ejaculates from six jacks were collected and analyzed for the present study. The freshly collected semen sample of each jack stallion was divided into five equal fractions after addition of the primary extender without cholesterol-loaded cyclodextrin (CLC) (C) and with 1, 1.5, 2, and 3 mg/mL CLC to obtain 120 × 106 sperm/mL spermatozoa concentration. The semen was cryopreserved using customized freezing protocols. Evaluation of seminal parameters, the C:P ratio, and the oxidative status of jack spermatozoa was analyzed at all stages of cryopreservation. The oxidative status in the jack semen was evaluated by measuring malondialdehyde, glutathione and total antioxidant capacity levels. The results indicated that the mean percent values for various seminal quality parameters and the oxidative parameters were found to be significantly higher (P < .05) in CLC-treated groups with the highest values for 2 mg of CLC/120 × 106 spermatozoa. In conclusion, the present study revealed that the supplementation of CLC before cryopreservation has significantly reduced the oxidative stress and also increased the C:P ratio during semen cryopreservation process. Furthermore, a reduction in lipid peroxidation levels, reduced damage to the sperm plasma and acrosome membranes and improvement in the post-thaw sperm integrity as well as stability were recorded.


Subject(s)
Cyclodextrins , Semen Preservation , Animals , Cholesterol , Cryopreservation/veterinary , Cryoprotective Agents/pharmacology , Cyclodextrins/pharmacology , Dietary Supplements , Horses , Male , Oxidative Stress , Phospholipids , Semen Analysis/veterinary , Semen Preservation/veterinary , Sperm Motility , Spermatozoa
7.
J Equine Vet Sci ; 93: 103193, 2020 10.
Article in English | MEDLINE | ID: mdl-32972675

ABSTRACT

Wound healing in horses is complicated by the excessive growth of granulation tissue, commonly known as proud flesh and is similar to keloids in human beings. At present, there is no satisfactory treatment for proud flesh in horses. In this study, we, for the first time, demonstrated that leaf extract of Aerva javanica suppresses excessive growth of granulation tissue in horses. Many plant flavonoids are claimed to have antiproliferative properties. Kaempferol is a natural flavonoid containing 3-hydroxy flavone backbone found in many plants in its aglycone form and attached with various sugars. Ecdysteroids are steroidal analogs of invertebrate steroidal hormones found in plants. Both flavonoids and ecdysteroids accumulate more in plants during abiotic stress. We hypothesized that Aerva javanica may have high levels of ecdysteroids and kaempferols for surviving in stressful conditions of desert. Those kaempferols may suppress the growth of granulation tissue by their antiangiogenesis property. Ecdysteroids may control the larvae of habronema if associated with proud flesh. Extract was prepared using solvent-based fractionation and silica gel column flash chromatography. Application of the leaf extract in horses suppressed growth of granulation tissue along with restoration of normal skin function. Various purification steps and mass spectrometry were used to identify the active components in the study.


Subject(s)
Amaranthaceae , Horse Diseases , Keloid , Animals , Granulation Tissue , Horses , Keloid/veterinary , Plant Extracts/pharmacology , Wound Healing
8.
Antiviral Res ; 181: 104870, 2020 09.
Article in English | MEDLINE | ID: mdl-32707051

ABSTRACT

We describe herein that Apigenin, which is a dietary flavonoid, exerts a strong in vitro and in ovo antiviral efficacy against buffalopox virus (BPXV). Apigenin treatment was shown to inhibit synthesis of viral DNA, mRNA and proteins, without affecting other steps of viral life cycle such as attachment, entry and budding. Although the major mode of antiviral action of Apigenin was shown to be mediated via targeting certain cellular factors, a modest inhibitory effect of Apigenin was also observed directly on viral polymerase. We also evaluated the selection of drug-resistant virus variants under long-term selection pressure of Apigenin. Wherein Apigenin-resistant mutants were not observed up to ~ P20 (passage 20), a significant resistance was observed to the antiviral action of Apigenin at ~ P30. However, a high degree resistance could not be observed even up to P60. To the best of our knowledge, this is the first report describing in vitro and in ovo antiviral efficacy of Apigenin against poxvirus infection. The study also provides mechanistic insights on the antiviral activity of Apigenin and selection of potential Apigenin-resistant mutants upon long-term culture.


Subject(s)
Antiviral Agents/pharmacology , Apigenin/pharmacology , Drug Resistance, Viral , Vaccinia virus/drug effects , Animals , Chick Embryo/virology , Chickens , Chlorocebus aethiops , DNA, Viral/genetics , DNA-Directed DNA Polymerase , Humans , Vaccinia virus/enzymology , Vero Cells , Virus Replication/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...